The latest medical insurance reimbursement conditions for dabrafenib have been announced!

The original drug of Dabrafenib (Dabrafenib) is approved for marketing in China as dabrafenib mesylate capsules, and is also marketed as Tefilla/ It is sold under the trade name of TAFINLAR. As of December 2023, dabrafenib mesylate capsules have passed the relevant regulations of the National Medical Insurance Bureau and entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. Patients who do not meet the conditions can only purchase this drug at their own expense. Therefore, reimbursement conditions include:

1. BRAF V600 mutation-positive unresectable or metastatic melanoma: combined with trametinib is suitable for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma;

2. Postoperative adjuvant treatment of BRAF V600 mutation-positive melanoma: combined with trametinib is suitable for adjuvant treatment of patients with BRAF V600 mutation-positive stage III melanoma after complete resection;

3. BRAF V600 mutation-positive metastatic non-small cell lung cancer: combined with trametinib is suitable for the treatment of patients with BRAF V600 mutation-positive metastatic non-small cell lung cancer.

The original drug of dabrafenib sold in China is relatively expensive, and the price of the specification50mg*120 capsules per box may be around 10,000. The Turkish version of dabrafenib original drug sold overseas, with a specification of 75mg*120 pills, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 75mg*120 tablets produced by a Lao pharmaceutical factory may be more than 4,000 yuan (the price may fluctuate due to exchange rates).